Status:
COMPLETED
Korean Post-marketing Surveillance for Reyataz®
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV-1
Eligibility:
All Genders
Brief Summary
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Reyataz® ...
Eligibility Criteria
Inclusion
- Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
Exclusion
- According to Warning/Caution in local label
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
601 Patients enrolled
Trial Details
Trial ID
NCT01450605
Start Date
December 1 2011
End Date
March 1 2016
Last Update
April 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Seoul, South Korea, 110-756